跳至主要内容
临床试验/CTRI/2023/02/049470
CTRI/2023/02/049470已完成Phase 3 4

A double blind, randomized, crossover, two period, parallel group, single center, placebocontrolled study to evaluate safety and efficacy of WSCS IIIM (comprising extract A andExtract B) for sleep disorder(s) in otherwise healthy volunteers

CSIR Indian Institute of Integrative Medicine1 个研究点 分布在 1 个国家目标入组 40 人开始时间: 2023年10月2日最近更新:

试验速览

阶段
Phase 3 4
状态
已完成
入组人数
40
试验地点
1
主要终点
1. The primary end point is completion of 1-week treatment sessions on Day 0 and Day 8 with

研究概览

简要总结

The objective of this study is to validate the safety & efficacy of oral administration of Ashwagandha capsule (comprising extract A and Extract B) for sleep disorder (Insomnia) in otherwise healthy volunteersInsomnia, also known as sleeplessness, is a sleep disorder in which people have trouble sleeping. They may have difficulty falling asleep, or staying asleep as long as desired. Insomnia is typically followed by daytime sleepiness, low energy, irritability, and a depressed mood. It may result in an increased risk of motor vehicle collisions, as well as problems focusing and learning.

Withania somnifera, known commonly as Ashwagandha or winter cherry, is an evergreen shrub in the Solanaceae or nightshade family that grows in India, the Middle East, and parts of Africa.

Several other species in the genus Withania are morphologically similar. It has been traditionally known since ancient times in India for its numerous beneficial health activities. WS is one of the most important herbs in Ayurveda, which has been used for >3000 years in stress management, energy elevation and improving cognitive health and to lower inflammation, blood sugar levels, cortisol, anxiety, and depression. The plant is an erect, grayish, evergreen shrub with long tuberous roots, short stems, ovate and petiolate leaves, and greenish axillary and bisexual flowers. The leaves, roots, stems and flowers bear medicinal values with 29 common metabolites derived from the leaves

and root extracts. To date, this medicinal plant has been found to have anti-epileptic, antiinflammatory, anti-arthritic, anti-depressant, anti-coagulant, anti-oxidant, anti-diabetic, anti-pyretic efficacies along with palliative effects such as analgesic, rejuvenating, regenerating and growthpromoting effects.

研究设计

研究类型
Interventional
分配方式
Computer generated randomization
盲法
Double Blind Double Dummy

入排标准

年龄范围
18.00 Year(s) 至 72.00 Year(s)(—)
性别
All

入选标准

  • Male volunteers who are 18 or older to 72 years.
  • Insomnia Severity Index 10-14
  • Meet diagnostic criteria for Insomnia Disorder per DSM-5
  • Willing and able to sign Informed consent form
  • Not planning on moving away from the area for the subsequent 12 weeks 6.Subjects should not have Milk during the study.

排除标准

  • Night shift workers and individuals who nap 3 or more times per week over the preceding month
  • Consumption of caffeine beverages tea, coffee, or cola comprising usually more than 5 cups or glasses per day
  • Participation in another trial for insomnia
  • Subjects having milk on regular basis.
  • Persons who are unable to participate for the entire duration of the study, or in the opinion of the investigators, are likely to be noncompliant with the obligations inherent in the trial participation
  • Persons self describing with severe anxiety or severe depression BDI score of 29 or higher or severe anxiety BAI score of 36 or higher
  • Persons with a history of epilepsy, seizures, or dementia any significant, severe or unstable, acute progressive medical or surgical condition stroke or head injury
  • Current alcohol or substance abuse/dependence must have greater than90 days of sobriety
  • Presence of other neurological disorders Ex multiple sclerosis, Parkinsons Disease
  • Presence of an untreated or unstable medical or psychiatric comorbid condition ex major depressive disorder or psychotic disorder requiring admission within the last two years People using psychotropic medication hypnotic or sedative medications may be included if they are on a stable dosage for the last 2 months prior to the study, if the dose remains stable throughout the study, and if the medication is judged to not interfere with the study outcomes.
  • Currently on medications known to produce insomnia ex.

结局指标

主要结局

1. The primary end point is completion of 1-week treatment sessions on Day 0 and Day 8 with

时间窗: Day 0 & Day 8.

2. Improvement of insomnia outcome is measured by Insomnia Severity Index (ISI), selfreported

时间窗: Day 0 & Day 8.

questionnaire, actigraphy, polysmonography on Day 0 & Day 8.

时间窗: Day 0 & Day 8.

cross over assessment.

时间窗: Day 0 & Day 8.

次要结局

  • The Secondary end point is improvement in biomarker values from Day 0 to Day 8(Day 0 & Day 8.)

研究者

申办方类型
Research institution

研究点 (1)

Loading locations...

相似试验

Clinical trial on sleep disorders | 临床试验